Menlo Park, Calif. and Dallas, Texas – June 14, 2021 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNPTM platform for the treatment of life-limiting respiratory diseases, today announced that the Company will participate in two upcoming virtual investor conferences in June:
- JMP Securities Life Sciences Conference
Format: Presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1×1 meetings
Date: Wednesday, June 16, 2021
Time: 4:00 – 4:25 p.m. ET
The presentation will be webcast live and available for replay here. - LifeSci Partners Genetic Medicines Summit
Format: Presentation and Q&A by David Lockhart, Ph.D., CEO and President
Date: Tuesday, June 22, 2021
Time: 1:00 – 1:25 p.m. ET
An archived replay of the presentation will be made available on the Company’s website following the presentation.
About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNPTM platform to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its SORT-LNPTM and nucleic acid technologies, utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.
Media Contact:
Will Zasadny
Canale Communications, Inc.
[email protected]
(619) 961-8848
Investor Contact:
Sarah McCabe
Stern Investor Relations
[email protected]
[email protected]
